Is Regeneron Pharmaceuticals Stock a Good Investment?
Regeneron Pharmaceuticals Investment Advice | REGN |
- Examine Regeneron Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Regeneron Pharmaceuticals' leadership team and their track record. Good management can help Regeneron Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Regeneron Pharmaceuticals' business and its evolving consumer preferences.
- Compare Regeneron Pharmaceuticals' performance and market position to its competitors. Analyze how Regeneron Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Regeneron Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Regeneron Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Regeneron Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Regeneron Pharmaceuticals is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Very Small | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Regeneron Pharmaceuticals Stock
Researching Regeneron Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 91.0% of the company shares are owned by institutional investors. The book value of Regeneron Pharmaceuticals was at this time reported as 272.04. The company has Price/Earnings To Growth (PEG) ratio of 1.1. Regeneron Pharmaceuticals recorded earning per share (EPS) of 40.44. The entity had not issued any dividends in recent years.
To determine if Regeneron Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Regeneron Pharmaceuticals' research are outlined below:
| Regeneron Pharmaceuticals generated a negative expected return over the last 90 days | |
| Regeneron Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Dremio Ranked Number 268 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500 |
Regeneron Pharmaceuticals Quarterly Cost Of Revenue |
|
Regeneron Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Regeneron Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Regeneron Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 2nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 2nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Regeneron Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Regeneron Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2004-07-26 | 2004-06-30 | -0.3 | -0.26 | 0.04 | 13 | ||
1999-10-28 | 1999-09-30 | -0.2 | -0.16 | 0.04 | 20 | ||
2008-11-04 | 2008-09-30 | -0.32 | -0.27 | 0.05 | 15 | ||
2000-07-27 | 2000-06-30 | -0.13 | -0.08 | 0.05 | 38 | ||
1997-08-01 | 1997-06-30 | -0.21 | -0.16 | 0.05 | 23 | ||
2012-02-13 | 2011-12-31 | -0.6 | -0.54 | 0.06 | 10 | ||
2010-07-28 | 2010-06-30 | -0.37 | -0.31 | 0.06 | 16 | ||
2010-10-28 | 2010-09-30 | -0.34 | -0.41 | -0.07 | 20 |
Know Regeneron Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Regeneron Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Regeneron Pharmaceuticals backward and forwards among themselves. Regeneron Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Regeneron Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Loomis, Sayles & Company Lp | 2024-06-30 | 1.2 M | Norges Bank | 2024-06-30 | 1.1 M | Amundi | 2024-06-30 | 1.1 M | Wellington Management Company Llp | 2024-06-30 | 1.1 M | Legal & General Group Plc | 2024-06-30 | 978.1 K | Bank Of America Corp | 2024-06-30 | 968.1 K | T. Rowe Price Associates, Inc. | 2024-06-30 | 932.9 K | Northern Trust Corp | 2024-09-30 | 918.6 K | Amvescap Plc. | 2024-06-30 | 916.4 K | Fmr Inc | 2024-09-30 | 10.4 M | Vanguard Group Inc | 2024-09-30 | 9.3 M |
Regeneron Pharmaceuticals' market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 81.1 B.Market Cap |
|
Regeneron Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.12 | 0.13 | |
| Return On Capital Employed | 0.14 | 0.14 | |
| Return On Assets | 0.12 | 0.13 | |
| Return On Equity | 0.15 | 0.16 |
Determining Regeneron Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Regeneron Pharmaceuticals is a good buy. For example, gross profit margin measures Regeneron Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Regeneron Pharmaceuticals' profitability and make more informed investment decisions.
Regeneron Pharmaceuticals' Earnings Breakdown by Geography
Evaluate Regeneron Pharmaceuticals' management efficiency
Regeneron Pharmaceuticals has return on total asset (ROA) of 0.0741 % which means that it generated a profit of $0.0741 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1717 %, meaning that it created $0.1717 on every $100 dollars invested by stockholders. Regeneron Pharmaceuticals' management efficiency ratios could be used to measure how well Regeneron Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of November 2024, Return On Tangible Assets is likely to grow to 0.13. Also, Return On Capital Employed is likely to grow to 0.14. At this time, Regeneron Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 24th of November 2024, Return On Tangible Assets is likely to grow to 0.13, while Other Current Assets are likely to drop about 197.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 243.42 | 255.59 | |
| Tangible Book Value Per Share | 233.69 | 245.37 | |
| Enterprise Value Over EBITDA | 20.13 | 21.14 | |
| Price Book Value Ratio | 3.61 | 5.22 | |
| Enterprise Value Multiple | 20.13 | 21.14 | |
| Price Fair Value | 3.61 | 5.22 | |
| Enterprise Value | 38.4 B | 40.3 B |
At Regeneron Pharmaceuticals, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta 0.142 |
Basic technical analysis of Regeneron Stock
As of the 24th of November, Regeneron Pharmaceuticals holds the Variance of 2.84, coefficient of variation of (239.61), and Risk Adjusted Performance of (0.31). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Regeneron Pharmaceuticals, as well as the relationship between them.Regeneron Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regeneron Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regeneron Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Regeneron Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Andrew Murphy over six months ago Disposition of tradable shares by Andrew Murphy of Regeneron Pharmaceuticals at 962.87 subject to Rule 16b-3 | ||
Arthur Ryan over six months ago Disposition of tradable shares by Arthur Ryan of Regeneron Pharmaceuticals at 986.58 subject to Rule 16b-3 | ||
Huda Zoghbi over a year ago Exercise or conversion by Huda Zoghbi of 1000 shares of Regeneron Pharmaceuticals subject to Rule 16b-3 | ||
Huda Zoghbi over a year ago Exercise or conversion by Huda Zoghbi of 1706 shares of Regeneron Pharmaceuticals subject to Rule 16b-3 | ||
Huda Zoghbi over a year ago Exercise or conversion by Huda Zoghbi of 1706 shares of Regeneron Pharmaceuticals subject to Rule 16b-3 |
Regeneron Pharmaceuticals' Outstanding Corporate Bonds
Regeneron Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Regeneron Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Regeneron bonds can be classified according to their maturity, which is the date when Regeneron Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| REGENERON PHARMACEUTICALS INC Corp BondUS75886FAF45 | View | |
| REGENERON PHARMACEUTICALS INC Corp BondUS75886FAE79 | View | |
| US75884RBA05 Corp BondUS75884RBA05 | View | |
| REGENCY CTRS L Corp BondUS75884RAV50 | View | |
| US75884RAW34 Corp BondUS75884RAW34 | View | |
| REGENCY CTRS L Corp BondUS75884RAU77 | View | |
| US75884RAZ64 Corp BondUS75884RAZ64 | View |
Understand Regeneron Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Regeneron Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.31) | |||
| Market Risk Adjusted Performance | (0.86) | |||
| Mean Deviation | 1.16 | |||
| Coefficient Of Variation | (239.61) | |||
| Standard Deviation | 1.69 | |||
| Variance | 2.84 | |||
| Information Ratio | (0.49) | |||
| Jensen Alpha | (0.81) | |||
| Total Risk Alpha | (0.98) | |||
| Treynor Ratio | (0.87) | |||
| Maximum Drawdown | 11.18 | |||
| Value At Risk | (3.28) | |||
| Potential Upside | 0.9993 | |||
| Skewness | (2.23) | |||
| Kurtosis | 8.94 |
| Risk Adjusted Performance | (0.31) | |||
| Market Risk Adjusted Performance | (0.86) | |||
| Mean Deviation | 1.16 | |||
| Coefficient Of Variation | (239.61) | |||
| Standard Deviation | 1.69 | |||
| Variance | 2.84 | |||
| Information Ratio | (0.49) | |||
| Jensen Alpha | (0.81) | |||
| Total Risk Alpha | (0.98) | |||
| Treynor Ratio | (0.87) | |||
| Maximum Drawdown | 11.18 | |||
| Value At Risk | (3.28) | |||
| Potential Upside | 0.9993 | |||
| Skewness | (2.23) | |||
| Kurtosis | 8.94 |
Consider Regeneron Pharmaceuticals' intraday indicators
Regeneron Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Regeneron Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.0183 | |||
| Daily Balance Of Power | (0.47) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 744.52 | |||
| Day Typical Price | 742.34 | |||
| Market Facilitation Index | 13.77 | |||
| Price Action Indicator | (9.76) | |||
| Period Momentum Indicator | (6.50) | |||
| Relative Strength Index | 14.8 |
Regeneron Pharmaceuticals Corporate Filings
F4 | 12th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 31st of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Regeneron Stock media impact
Far too much social signal, news, headlines, and media speculation about Regeneron Pharmaceuticals that are available to investors today. That information is available publicly through Regeneron media outlets and privately through word of mouth or via Regeneron internal channels. However, regardless of the origin, that massive amount of Regeneron data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Regeneron Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Regeneron Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Regeneron Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Regeneron Pharmaceuticals alpha.
Regeneron Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Regeneron Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Regeneron Pharmaceuticals Historical Investor Sentiment
Investor biases related to Regeneron Pharmaceuticals' public news can be used to forecast risks associated with an investment in Regeneron. The trend in average sentiment can be used to explain how an investor holding Regeneron can time the market purely based on public headlines and social activities around Regeneron Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Regeneron Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Regeneron Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Regeneron Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals Corporate Management
| Joseph JD | General VP | Profile | |
| Patrice Gilooly | Senior Operations | Profile | |
| Andrew Murphy | Executive Research | Profile | |
| Christopher CPA | Head Finance | Profile | |
| Bob McCowan | Senior Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.298 | Earnings Share 40.44 | Revenue Per Share 128.691 | Quarterly Revenue Growth 0.106 | Return On Assets 0.0741 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Regeneron Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.